Dr. Lox on AVN New Treatments with Regenerative Medicine

-Avascular or loss of blood flow to a region

-Necrosis or bone cell death

-AVN is often called by other names especially in other countries, most commonly Osteonecrosis.

Other names used for AVN are aseptic Necrosis, bone infarction.

AVN can sometimes refer to A specific bone with a different name.

Just to add a little more confusion to the term Avascular Necrosis specific names of the bone involved may be used, often the name of the first physician who described the condition.

-Kienbocks

-Kohlers

-Freibergs

-Deitrichs

-Legg-Calve-Perthes

-Preisers

-Thiemans

There are many patients looking earlier to Regenerative Medicine and Stem Cell Therapy as options. Before often there were given either get a joint replacement surgery or fusion or wait till it is bad enough. These answers are not satisfactory to proactive patients, parents, and especially athletes.  With many famous name professional athletes having stated they opted for Regenerative Medicine and Stem Cell Therapy, there is less of a stigma or fear of the unknown now compared to 10 years ago. Dennis M. Lox M.D. is an expert in Sports and Regenerative Medicine and has seen the changes in the last decade. It not as much advancement in what we do, it is more knowledge of what the stem cell can or cannot do. Some old assumptions that more stem cells were better if cultured to higher yields, did not bear out in long term studies. Additionally, we know the homing capacity of stem cells is impaired by multiple cell divisions in a lab. It is wise to stay with the same day, the same person FDA rule as its not just smart scientific-based medicine, it’s the rules. Anything outside the same day is not the practice of medicine, it falls into the realm of drug therapy. Thus it must be approved as a drug.  Perinatal Tissue’s Placenta, Amniotic, Cord Blood, Umbilical tissue are labeled by the FDA as medical devices, not as approved drugs. This is because if it were a pure stem cell product it would fall into the category of being approved as a drug, which they are not. There are presently two cord blood hematopoietic drugs approved for use in specific conditions. The many center’s confusing patients tissue types younger is better, or placental, amniotic, or any other perinatal tissue are just misinforming patients. Dr. Lox has lectured twice at the International Perinatal Society Meeting once in Aspen, and once in Teaneck, New Jersey.  The purpose was a future view from Dr. Lox’s perspective on perinatal cells of drug origin, combined in some cases with the patients own cells for sports medicine.  Dr. Lox’s expertise in both fields was used to spark discussions of the future.  This has nothing to do with tissue grafts approved for wound therapy as medical devices. This is where the continued propagation of misinformation to patients continues to occur by multiple parties that either doesn’t know, or ignore the difference, and misinformation to patients occurs. It is important to know a Regenerative Medicine specialist true credentials.